News

Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a sharehold ...
Patients with ID receiving TNF inhibitors are at greater risk for cutaneous malignancy than patients who are biologic-naïve.
WFTS Tampa, FL on MSN1h
Philip Collins | Morning Blend
Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...
Nearly nine million people in the U.S. have an inflammatory skin condition called plaque psoriasis. We're raising awareness ...
A potential world-first cure for hepatitis B, a breakthrough treatment for a rare, life-threatening childhood disease, and a ...
Dawn foaming dish spray works superbly and most professional cleaners will tell you that you can use it to clean more than ...
A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...
Lady T is joined by Dr. Mona Gohara, Medical Dermatologist and Associate Clinical Professor at the Department of Dermatology ...
Mental and skin health experts have raised concerns over the rising number of Nigerians battling depression and mental health disorders as a result of chronic skin conditions such as eczema, psoriasis ...
This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...
A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...